78 results about "Nonsense mutation" patented technology

The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI surface so as to provide for phenotypic suppression of the nonsense mutation.

The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.

The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

The present invention comprises compositions for treating diseases caused by nonsense mutations, including dipeptide antibiotics of Formula (I) shown below, such as negamycin. Unlike aminoglycoside antibiotics such as gentamicin, dipeptide antibiotics can induce the expression of mature proteins by readthrough nonsense mutations without generating serious side effects.

The invention concerns mutant L. bulgaricus strains bearing a nonsense mutation, in at least one of the sequences coding for the lactose operon, and free from β-galactosidase activity, and lactic starters comprising these strains. The strains and starters can be used to obtain fermented milk products from glucose-added milk.

The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.

A method of expressing a protein having an unnatural amino acid integrated thereinto characterized by comprising expressing (A) a mutant tyrosyl tRNA synthase which is a mutant of Escherichia coli-origin tyrosyl tRNA synthase and has an elevated specificity for a unnatural tyrosine derivative compared with the specificity for tyrosine, (B) a suppressor tRNA originating in an eubacterium belonging to the genus Bacillus, Mycoplasma or Staphylococcus which is capable of binding to the above tyrosine derivative in the presence of the above mutant TyrRS, and (C) a desired protein gene having a nonsense mutation at a desired site in animal cells to thereby incorporate the above tyrosine derivative into the nonsense mutation site in the above protein.

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

The invention relates to an I type neurofibroma NF1 gene mutation nucleotide sequence related to cerebrovascular stenosis and application thereof. Compared with a corresponding nucleotide sequence contained in NF1, the nucleotide sequence related to cerebrovascular stenosis, which is disclosed by the invention, is mutated at the following position: c.541C>T; the mutation position is started from a first base in a gene coding region of NF1; and the mutation causes a patient to suffer from cerebrovascular stenosis. Research finds that the nonsense mutation exists in all NF1 family patients suffering from cerebrovascular stenosis, but does not exist in normal people in the NF1 family. The mutational site can provide basis for establishing a similar clinical symptom cerebrovascular stenosis animal model and is further used for carrying out super early diagnosis and prevention on the sporadic potential cerebrovascular stenosis of NF1 patients.

The invention discloses a CRISPR single-base restoration system. The CRISPR single-base restoration system is capable of expressing eukaryotic expression vectors of sgRNA and Cas9 and single strandedoligonucleotide as a donor template, wherein the base sequence of single stranded oligonucleotide is basically the same as the base sequence between bases 30-60 on two sides of a to-be-restored singlebase, and the differences between the two base sequences are that the base corresponding to the to-be-restored single base is a non-mutation wild base, and nonsense mutation occurs on one side of theto-be-restored single base. The invention further discloses application of the CRISPR single-base restoration system in the preparation of drugs for treating beta thalassemia caused due to CD17A-T point mutation of a beta bead protein gene. According to the CRISPR single-base restoration system, a CRISPR/Cas expression plasmid and a donor are commonly transfected into cells, the traceless directional transformation of gene mutation sites in beta17 thalassemia is specifically induced in a 293TT cell, and the method has very important clinical application values in the execution of gene editingaccurate treatment on diseases based on single-gene point mutation.

Contemplated systems and methods integrate genomic/exomic data with transcriptomic data by correlating a cancer associated mutation in the genome/exome with the transcription level of the affected gene carrying the mutation, particularly where the mutation is a 3-terminal nonsense mutation.

[Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound.

[Solution] A compound represented by the following general formula (1):

and a pharmaceutical composition containing this compound.

The molecular mechanism underlying degenerative joint disease, also known as osteoarthritis (OA), is not fully understood. Disruption of mitogen inducible gene 6 (Mig-6) in mice by homologous recombination (KO mice) led to early onset OA as revealed by simultaneous enlargement and deformity of multiple joints, degradation of articular cartilage and the development of bony outgrowths or osteophytes within the joint space. The latter appeared to be derived from proliferation of mesenchymal progenitor cells followed by differentiation into chondrocytes. Because of the striking similarity to human OA, Mig-6 KO mice are a useful animal model for studying the mechanism of this disease and for testing new drugs or therapies for treating OA. These KO mice also developed epithelial hyperplasia, adenoma, and adenocarcinoma in organs such as lung, gallbladder, and bile duct. Mig-6 is therefore a tumor suppressor gene and is a candidate gene for the frequent Ip36 genetic alterations found in lung cancer. It can be used as a tumor biomarker as well as a target for cancer therapy. Mig-6 is located in human chromosome Ip36, a locus frequently associated with human lung cancer. Mig-6 is a negative regulator of EGF signaling, and like EGF, was induced by HGF/SF in human lung cancer cell lines. Frequently the receptors EGFR and Met were co-expressed, and Mig-6 was induced by both EGF and HGF/SF in a MAPK-dependent fashion. Not all tumor lines express Mig-6 in response to either EGF or HGF/SF. In these cases, missense and nonsense mutations in the Mig-6 coding region were found, as was evidence for Mig-6 transcriptional silencing.

Methods for modifying a dystrophin gene are disclosed, for restoring dystrophin expression within a cell having an endogenous frameshift or nonsense mutation within the dystrophin gene. The methods comprise introducing a first cut within an exon en or intron of the dystrophin gene creating a first exon end or intron end, wherein said first cut is located upstream of the endogenous frameshift or nonsense mutation; and introducing a second cut within an exon or intron of the dystrophin gene creating a second exon end or intron end, wherein said second cut is located downstream of the frameshift or nonsense mutation. Upon joining/ligation of said first and second exon ends or intron ends a hybrid exon or intron junction is created and dystrophin expression is restored, as the correct reading frame is restored. Reagents and uses of the method are also disclosed, for example to treat a subject suffering from muscular dystrophy.

The present invention relates to a cSNP molecular marker detection kit and a detection method for scylla paramamosain disease-resistant characters, relates to the technical field of molecule auxiliary disease resistance breeding in aquatic livestock, and particularly relates to a single nucleotide polymorphism cSNP molecular marker, capable of influencing disease resistance of blue crabs, in a cDNA sequence of scylla paramamosain SpALF6, as well as a detection kit and a detection method thereof. On a basis that a disease resistance factor SpALF6 of the scylla paramamosain is identified, by performing sequence comparison, it is found that 215th nucleotide in the cDNA sequence of SpALF6 and 222th nucleotide G of a variant of the SpALF6, namely SpALF6-V, are nonsense mutation for each other. In the invention, the mutation site is used as the basis, a convenient and practical molecular marker detection kit is built, and a matched RT-PCR detection method is provided; detection results can be used as important indicators for judging the disease resistance of the blue crabs, and the single nucleotide polymorphism cSNP molecular marker has the great importance in predicting of the disease resistance of the blue crabs and molecule auxiliary disease resistance breeding.

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

The invention relates to a human induced pluripotent stem cell strain SXMUi002-A-1. The human induced pluripotent stem cell strain SXMUi002-A-1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human induced pluripotent stem cell strain SXMUi002-A-1 is CGMCC No: 22359. The iPSC is obtained by extracting urine cells from urine of a B-type hemophilia patient carrying F9c.223C>T(p.R75X) nonsense mutation and reprogramming, and further research finds that the iPSC is similar to an embryonic stem cell in the aspects of cellular morphology, gene expression, proliferation and differentiation potential and has the potential of differentiating to three germ layers. The prepared human induced pluripotent stem cell strain SXMUi002-A-1 has important value for molecular mechanism research of hemophilia nonsense mutation, hemophilia detection, drug screening, gene therapy and other clinical application researches, and provides important resources.

A novel polypeptide and a novel polynucleotide encoding the same are disclosed. The polypeptide is SMG-1, a protein included in the phosphatidyl inositol kinase related kinase family, and is useful in constructing a screening system for agents of treating and/or preventing a disease caused by a premature translation termination codon generated by a nonsense mutation.

Animals with mutations in COL4α4 present with autosomal recessive Alport Syndrome (ARAS). Through sequencing of COL4α4, the mutation causative for ARAS in the English Cocker Spaniel (ECS) has been identified. The resulting protein is severely truncated due to a premature stop codon in exon 3. This nonsense mutation occurs in the 7S domain and also causes the loss of the entire collagenous and NC1 domains of the protein. Methods for the identification of animals that harbor a mutation in the COL4α4 gene are described. Mutations in the COL4α4 gene can be identified from any biological sample such as a cell or tissue that contains genomic DNA. Methods for identifying single nucleotide polymorphisms (SNPs) that are inherited with the disease are also described. A microsatellite marker that segregates with ARAS is also described that was identified using linkage disequilibrium mapping.